REGENCELL BIOSCIENCE HOLDING
RGCNASDAQTrading Snapshot
- Day Range
- $4.97 – $5.09
- 52-Week Range
- $4.51 – $69.00
- Volume
- $3.09B
- Avg Volume
- $3.91B
- Shares Outstanding
- 495.5M
- Next Earnings
- Oct 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $259M
- Last Q Revenue
- $67M
- P/E Ratio
- -353.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.01
- Dividend Yield
- 0.00%
Why Investors Own RGC
- ✓High-growth profile — revenue up +16.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About REGENCELL BIOSCIENCE HOLDING
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Otter Score Breakdown
ⓘAnalyst Price Target
ⓘLatest News & Updates
Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On Tuesday
Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers include PHOE, SKHY, GALT, AXTI, FCEL, AAOI, CHRN, TSEM, YSS, RGC, and OKTA.
Top movers in Tuesday's pre-market session
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.